Omiganan
Also known as: CLS001, MBI 226, MBX‑100, Omiganan, Omiganan pentahydrochloride, Pexiganan analogue
Source Omiganan at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Omiganan (MBX‑100) is a synthetic 12‑amino‑acid cationic antimicrobial peptide derived from indolicidin, studied as a topical acne treatment and as a catheter‑lock solution to prevent bloodstream infections.
Mechanism of Action
Disrupts bacterial cell membranes causing rapid bacterial death; also exerts immunomodulatory effects on host cells
Routes of Administration
Goals & Uses
- Prevention of catheter‑related bloodstream infectionsInfection ProphylaxisModerate
- Treatment of inflammatory rosaceaDermatologyModerate
- Treatment of mild to moderate acne vulgarisDermatologyModerate
- Broad-spectrum antimicrobial activity (gram-positive, gram-negative, fungi)Anti InfectiveModerate
- Treatment of acne vulgarisDermatologyLow
- Prevention of catheter-related bloodstream infectionsAnti Infective / ProphylaxisModerate
Contraindications
- Application to open wounds or mucous membranes (outside studied indications)SafetyModerate
- Hypersensitivity to Omiganan or formulation componentsAllergyHigh
- Known hypersensitivity to omiganan or related peptidesAllergyHigh
Adverse Effects
- Local skin irritationDermatologicalCommon
- PruritusDermatologicUncommonItching
- Contact dermatitisDermatologicalUncommon
- Application site irritationLocal/dermatologicalCommon
- Systemic toxicitySystemicRare
- erythemaLocalCommon
Drug Interactions
- none identifiedLow
- Other topical antimicrobialsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatrics (<12 years)AgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with compromised skin barrierDisease RelatedRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing; not authorized
- United StatesInvestigationalUnder IND for catheter lock and acne studies
- United KingdomInvestigationalNo marketing authorization
No regulatory approval as of 2024; Phase III trials completed but not submitted for marketing.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Omiganan?
Omiganan (MBX‑100) is a synthetic 12‑amino‑acid cationic antimicrobial peptide derived from indolicidin, studied as a topical acne treatment and as a catheter‑lock solution to prevent bloodstream infections.
What is Omiganan used for?
Omiganan is educationally associated with: Prevention of catheter‑related bloodstream infections, Treatment of inflammatory rosacea, Treatment of mild to moderate acne vulgaris, Broad-spectrum antimicrobial activity (gram-positive, gram-negative, fungi), Treatment of acne vulgaris, Prevention of catheter-related bloodstream infections. Educational only — not medical advice.
How is Omiganan administered?
Recorded routes of administration: Intravenous Catheter Lock, Topical.
What are the potential side effects of Omiganan?
Reported adverse effects include: Local skin irritation, Pruritus, Contact dermatitis, Application site irritation, Systemic toxicity, erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Omiganan?
Recorded contraindications: Application to open wounds or mucous membranes (outside studied indications), Hypersensitivity to Omiganan or formulation components, Known hypersensitivity to omiganan or related peptides. Consult a qualified clinician before use.